Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content

Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies. Sirolimus has low oral bioavailability and exhibits large pharmacokinetic variability. The underlying mechanisms for this variability have not been explored to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Emoto, C, Fukuda, T, Cox, S, Christians, U, Vinks, A A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731827/
https://www.ncbi.nlm.nih.gov/pubmed/23884207
http://dx.doi.org/10.1038/psp.2013.33

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731827/
https://www.ncbi.nlm.nih.gov/pubmed/23884207
http://dx.doi.org/10.1038/psp.2013.33

Ejemplares similares